Journal ArticleDOI
Microbial natural products: molecular blueprints for antitumor drugs
Reads0
Chats0
TLDR
This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds.Abstract:
Microbes from two of the three domains of life, the Prokarya, and Eukarya, continue to serve as rich sources of structurally complex chemical scaffolds that have proven to be essential for the development of anticancer therapeutics. This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds. In every case, a microbe has been either identified as the producer of secondary metabolites or speculated to be involved in the production via symbiotic associations. Finally, rapidly evolving next-generation sequencing technologies have led to the increasing availability of microbial genomes. Relevant examples of genome mining and genetic manipulation are discussed, demonstrating that we have only barely scratched the surface with regards to harnessing the potential of microbes as sources of new pharmaceutical leads/agents or biological probes.read more
Citations
More filters
Journal ArticleDOI
Natural product discovery: past, present, and future
Leonard Katz,Richard H. Baltz +1 more
TL;DR: Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.
Journal Article
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION
TL;DR: Rapamycin is a new antifungal antibiotic produced by Streptomyces hygroscopicus and can be classified as a triene, highly active against various Candida species, especially Candida albicans.
Journal ArticleDOI
Metabolite induction via microorganism co-culture: A potential way to enhance chemical diversity for drug discovery
TL;DR: Co-culture studies that aim to increase the diversity of metabolites obtained from microbes, with a special emphasis on the multiple methods of performing co-culture experiments, are focused on.
Journal ArticleDOI
A Review of the Microbial Production of Bioactive Natural Products and Biologics.
Janette V. Pham,Mariamawit A. Yilma,Adriana Feliz,Murtadha T. Majid,Nicholas Maffetone,Jorge R. Walker,Eunji Kim,Hyo Je Cho,Jared M. Reynolds,Myoung Chong Song,Sung Ryeol Park,Sung Ryeol Park,Yeo Joon Yoon +12 more
TL;DR: The structures and diverse biological activities of natural products and recombinant proteins that have been exploited as valuable molecules in medicine, agriculture and insect control are introduced and suggested to inspire the development of new therapeutic agents in academia and industry.
Journal ArticleDOI
Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review shows the compounds derived from marine sources that are currently in clinical trials against cancer and the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies.
References
More filters
Journal ArticleDOI
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick,Vinay K. Puduvalli,Marc C. Chamberlain,Martin J. van den Bent,Antoine F. Carpentier,Lawrence Cher,Warren P. Mason,Michael Weller,Shengyan Hong,Luna Musib,Astra M. Liepa,Donald Thornton,Howard A. Fine +12 more
TL;DR: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
Journal ArticleDOI
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Victoria M. Richon,Yael Webb,R Merger,Terry L. Sheppard,B Jursic,Lang Ngo,F Civoli,Ronald Breslow,Richard A. Rifkind,Paul A. Marks +9 more
TL;DR: Based upon their effective concentrations, the cross-resistance or sensitivity of an HMBA-resistant MEL cell variant, and differences in c-myb expression during induction, these differentiation-inducing hybrid polar compounds can be grouped into two subsets, HMBA/EMBA and SAHA/CBHA.
Journal ArticleDOI
Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
Kenneth L. Rinehart,Tom G. Holt,N. L. Fregeau,Justin G. Stroh,Paul A. Keifer,Furong Sun,Li H. Li,David G. Martin +7 more
TL;DR: Ecteinascidins 729, 743, 745, 759A,759B, and 770, tris(tetrahydroisoquinolines) with potent in vivo antitumor activity, have been isolated from the colonial tunicate EctEinascidia turbinata, and their structures have been assigned.
Journal ArticleDOI
Geldanamycin, a new antibiotic.
TL;DR: A new crystalline antimicrobial compound, geldanamycin, has been discovered in the culture nitrates of Streptomyces hygroscopicus var.
Journal ArticleDOI
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Xin-Yan Pei,Yun Dai,Steven Grant +2 more
TL;DR: Sequential exposure to bortezomib in conjunction with clinically relevant HDAC inhibitors potently induces mitochondrial dysfunction and apoptosis in human MM cells through a ROS-dependent mechanism, suggesting that a strategy combining these agents warrants further investigation in MM.
Related Papers (5)
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more